DRI Healthcare Trust

DRI Healthcare Trust is a pioneer in global pharmaceutical royalty monetization, providing capital to inventors, academic institutions, and biopharma companies to accelerate therapeutic innovation. The company's mission is to build a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world. Headquartered in Toronto, Canada, the Trust aims to acquire dependable, patent-protected cash flow streams derived from the sales of important drugs.

The Trust's core business involves offering capital solutions to innovators within the biopharmaceutical industry. It focuses on medicines that address unmet medical needs, cultivating a diversified portfolio across various therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, lysosomal storage disorders, and immunology. Since its founding in 1989, DRI Healthcare has deployed over $3.0 billion, acquiring more than 75 royalties on over 45 drugs, such as Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula, and Zytiga.

In recent developments, DRI Healthcare Trust completed the internalization of its investment management function on July 1, 2025, transitioning to an integrated organization. The company reported a record first-quarter total income of $50.6 million in Q1 2026, marking a 15% year-over-year increase. During this period, it successfully issued $250 million in Senior Secured Notes and repurchased preferred securities. Ali Hedayat serves as the Chief Executive Officer, with Gary Collins as the Executive Chair of the Board of Trustees, and Zaheed Mawani as the Chief Financial Officer, appointed effective October 1, 2025.